Source: Annual Congress 2004 - Infectious pneumonia and related diseases including tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jaccard-Stolz, M. Christ-Crain, M. M. Gencay, R. Bingisser, P. Huber, B. Müller, M. Tamm (Basel, Switzerland). Indication for antibiotic therapy in AECB: anthonisen‘s criteria versus procalcitonin. Eur Respir J 2004; 24: Suppl. 48, 435

Member's Comments

No comment yet.

Related content which might interest you: Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy Source: Breathe, 15 (4) 296; 10.1183/20734735.0258-2019 Year: 2019 Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis Source: Eur Respir Rev 2017; 26: 160073 Year: 2017 Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1234-1235 Year: 2007 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 “Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304. Source: Breathe, 15 (4) e152; 10.1183/20734735.5258-2019 Year: 2019 Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 An analysis of non-effective empiric antibacterial therapy in COPD acute exacerbation Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections Year: 2007 Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study Source: Eur Respir J 2005; 26: Suppl. 49, 464s Year: 2005 Impact of guidelines on HAP and VAP outcomes Source: Eur Respir Mon 2011; 53: 66-73 Year: 2011 Debate: Antibiotic treatment is contraindicated in acute bronchitis - CON Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis Year: 2008 Sputum purulence guided antibiotic therapy in patients with exacerbations of COPD requiring hospitalization Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017